ADDF’s new initiative aims to advance digital tools for Alzheimer's and dementias

As part of its Diagnostics Accelerator research program, the Alzheimer's Drug Discovery Foundation (ADDF) announced today a new initiative that aims to fast-track the development of digital tools for Alzheimer's disease and related dementias.

The Diagnostics Accelerator program was created in July 2018 with initial funding commitments totaling nearly $35 million from partners including ADDF Co-Founder Leonard Lauder, Bill Gates, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. Since its inception, the Diagnostics Accelerator program has welcomed additional funders such as The Association for Frontotemporal Degeneration. The latest to join this coalition of philanthropists include Jeff and MacKenzie Bezos, bringing the current program funding to nearly $50 million.

"The Diagnostics Accelerator brings together philanthropic capital with a venture investment mindset to advance bold new ideas for easier and more accurate diagnosis of Alzheimer's disease and related dementias," Lauder said. "Initially, our goal was to raise $35 million to be spent over the next three years. We have exceeded our goal."

In a Gates Notes post published today, Gates reiterated the progress advancing the science of biomarkers for early detection and diagnostics, noting, "It's hard to overstate how important finding a reliable, affordable, and easy-to-use diagnostic is for stopping Alzheimer's." Gates highlighted how the use of advanced technology and digital tools, such as blood tests and mobile phone apps, can help empower doctors, patients and caregivers, and ultimately lead to better outcomes.

The Diagnostics Accelerator was created to address the lack of biomarkers that easily and more specifically screen and diagnose patients, stage disease progression, monitor response to treatment, and improve the rigor and efficiency of clinical trials. All are critical to the development of effective drugs for the prevention and treatment of Alzheimer's.

"The interest from the philanthropic as well as the scientific community has been tremendous," said Howard Fillit, M.D., Founding Executive Director and Chief Science Officer of the Alzheimer's Drug Discovery Foundation. "The ADDF is excited to expand its research support for the development of digital biomarkers that will augment traditional lab tests and imaging tools with creative and cost-effective approaches to collect, track and analyze patient data."

Digital tools may allow the remote capture of changes in a patient's physical and mental status at various stages of Alzheimer's disease. Information gathered can span from cognitive assessments to motor ability to sleep disruptions. "This real-world evidence has the potential to add significant value to clinical trials, increasing patient engagement, enhancing monitoring, and greatly improving treatment outcomes," Dr. Fillit said.​

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research shows brain synchronization between humans and dogs